We are back in Barcelona for Reuters Pharma 2024, bringing you all the highlights and talking points from Day One of the conference. Stay tuned for updates throughout the day.
Our ability to turn great products into great medicines has never been more reliant on how we engage with our patients, yet we’re still falling short of expectations and failing to build su
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
